相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1969
暂无试验阶段数据
撤回
1
100.0%
暂无批准数据
- A landmark Swiss study presented at ESCMID Global 2026 demonstrates that antiretroviral therapy reduces accelerated biological aging in people with HIV by nearly four years. - Researchers developed a plasma proteomic aging clock using blood protein patterns, finding that untreated HIV infection accelerates biological age by a median of 10 years. - After an average of 1.55 years of ART treatment, participants showed a significant mean reduction of 3.7 years in proteomic age, with continued improvement over time. - The findings support early initiation of ART and suggest that biological recovery occurs through broader inflammatory and immune system remodeling beyond T-cell reconstitution alone.
- Alithea Genomics closed a CHF 6.9 million ($8.9 million) seed financing round led by Genku Ventures to commercialize large-scale RNA sequencing platforms for drug screening and toxicology applications. - The company's 1536-well MERCURIUS DRUG-seq kits enable processing of up to 1,536 RNA samples simultaneously, significantly reducing costs and time compared to traditional sequencing workflows. - Funding will support commercialization efforts and development of proprietary transcriptomic data assets to train AI and machine learning models for drug discovery. - Leadership changes include Frederik Decouttere transitioning from Chairman to CEO, while co-founder Riccardo Dainese moves to Chief Commercial Officer to focus on business development.
- TLC-2716, an oral liver X receptor inverse agonist, demonstrated significant lipid-lowering effects in a 14-day Phase 1 trial involving 100 healthy adults. - The drug reduced triglycerides by up to 38.5% and postprandial remnant cholesterol by up to 61% at the highest doses tested. - TLC-2716 specifically targets liver and gut LXR activity while avoiding systemic effects, addressing a long-standing challenge in lipid metabolism drug development. - All doses were well tolerated with no serious adverse events, supporting progression to Phase 2 trials in patients with hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease.
- Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms. - The partnership combines Proxygen's validated glue degrader discovery platform with Professor Bruno Correia's pioneering work in AI and structural modeling for protein design and therapeutic discovery. - The collaboration aims to systematically predict and validate neosubstrate-ligase interactions and design chemical matter capable of inducing targeted protein degradation across previously inaccessible target space. - This integrated approach is expected to accelerate glue degrader development with greater precision and scale, building on Proxygen's existing partnerships with major pharmaceutical companies including Merck KGaA and Merck & Co Inc.
- Researchers from Mass General Brigham and EPFL have developed a new class of soft, flexible auditory brainstem implants designed to overcome limitations of current rigid devices used in NF2 patients. - The novel implant features an elastic, multilayer construct with ultra-thin platinum electrodes and silicone that conforms closely to the brainstem's curved surface for more precise stimulation. - Preclinical testing in two macaques demonstrated the animals could consistently distinguish between different stimulation patterns, indicating high-resolution auditory perception potential. - Current conventional ABIs provide only modest benefits like basic sound awareness for lip reading, while the new design aims to improve hearing outcomes and reduce side effects.
